National Institute for Health and Care Excellence

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

The National Institute for Health and Care Excellence (NICE) is producing guidance on using EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer in the NHS ...
MedPage Today

EGFR Testing in Advanced NSCLC: Real-World Data Show Major Gaps

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
MedPage Today

In NSCLC, Detecting EGFR Mutations

"The real-time PCR using plasma or body fluids could be a suitable first test for the detection of EGFR mutations." –Lee et al., Asia-Pacific Journal of Clinical Oncology, 2022 To this end, Kyunghoon ...
Medscape

FDA OKs First Liquid Biopsy for Lung Cancer Mutation

The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
The Financial

Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...
The American Journal of Managed Care

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
Business Wire

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World ...

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib ...
Seeking Alpha

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
ascopubs.org

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing

Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities A total of 7,413 tumor specimens were tested. The ...
ascopubs.org

Magnetic resonance imaging–based deep learning for predicting EGFR mutations in metastatic non-small cell lung cancer: A systematic review and meta-analysis.

Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): A large national study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...